Roche’s Analyst Event at ISTH 2017

Please register to access the replay*

*Privacy notice

Webcast Replay

HAVEN2: Ph3 interim data of emicizumab (ACE910) prophylaxis in pediatrics with hemophilia A with inhibitors; aspects of disease management and emicizumab global development program
HAVEN1: Ph3 data of emicizumab (ACE910) prophylaxis in adults with hemophilia A with inhibitors
Gallia Levy, M.D., Ph.D., Global Development Team Leader emicizumab
Prof. Dr. med. Johannes Oldenburg, University Clinic Bonn, Institute of Experimental Hematology and Transfusion Medicine
Daniel O’Day, CEO Roche Pharmaceuticals
Past IR Events
View more Events


Related links